Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Fineline Cube Apr 30, 2026
Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026
Company Deals

CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma

Fineline Cube Aug 13, 2025

CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a...

Company Deals

Kangji Medical Proposes Privatization, Aiming to Delist from Hong Kong Stock Exchange

Fineline Cube Aug 13, 2025

Kangji Medical Holdings Limited (HKG: 9997) has submitted a proposal to its shareholders regarding a...

Company Drug

Hengrui Pharmaceuticals Expands Hetrombopag Olamine’s Indication for ITP Patients

Fineline Cube Aug 13, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the indication expansion for...

Others

Ascletis Pharma Reports Positive Preclinical Results for ASC47 in Obesity Treatment

Fineline Cube Aug 13, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced encouraging efficacy results from preclinical trials of ASC47,...

Company Deals

Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor

Fineline Cube Aug 13, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August...

Company Drug

Sino Biopharmaceutical’s TQB3142 IND Application Accepted by China’s NMPA for Malignant Tumor Treatment

Fineline Cube Aug 13, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that the Investigational New Drug (IND) application for TQB3142,...

Company Drug

Novartis’ Leqvio Approved by FDA as Standalone Therapy for Hypercholesterolemia

Fineline Cube Aug 13, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 12, 2025, that the U.S. Food...

Company Deals Drug

HighTide Therapeutics Collaborates with IMB to Assess HTD1801 in T2DM with CKD

Fineline Cube Aug 13, 2025

China-based HighTide Therapeutics, Inc. (HKG: 2511) announced the commencement of a collaborative project with the...

Policy / Regulatory

FDA Launches PreCheck Program to Strengthen U.S. Pharmaceutical Supply Chain

Fineline Cube Aug 13, 2025

The U.S. Food and Drug Administration (FDA) announced the launch of “FDA PreCheck” on August...

Company

Pfizer China Restructures Oncology and Rare Disease Units for Enhanced Focus

Fineline Cube Aug 13, 2025

Pfizer China (NYSE: PFE) announced on August 11, 2025, an organizational optimization of its Oncology and...

Policy / Regulatory

China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List

Fineline Cube Aug 12, 2025

China’s National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025...

Company

Legend Biotech Reports Q2 Revenue Growth of 36.7% and H1 Growth of 60.4%

Fineline Cube Aug 12, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) reported unaudited financial statements for the three months (Q2)...

Company

Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition

Fineline Cube Aug 12, 2025

Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) reported financial results for the first quarter of...

Company Drug

Hengrui’s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China’s NMPA

Fineline Cube Aug 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025,...

Policy / Regulatory

Macao Drug Administration Expands White List for Designated Medical Institutions in Cooperation Zone

Fineline Cube Aug 12, 2025

The Drug Administration of the Macao Special Administrative Region (SAR) of China has announced the...

Legal / IP

CureVac and GSK Resolve mRNA Vaccine Patent Dispute With BioNTech and Pfizer

Fineline Cube Aug 12, 2025

CureVac N.V. (NASDAQ: CVAC) announced on August 7, 2025, that it has reached an agreement...

Others

Shanghai Moyang Biotechnology Secures Hundreds of Millions in Funding to Expand Global Reach

Fineline Cube Aug 12, 2025

Shanghai Moyang Biotechnology Co., Ltd. announced on August 8, 2025, that it has successfully closed...

Company Drug

Novartis Begins Shipping Next-Gen Anti-VEGF Drug Beovu for Diabetic Macular Edema

Fineline Cube Aug 12, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 11, 2025, the initiation of commercial...

Company Drug

Arvinas and Pfizer’s Vepdegestrant NDA Accepted by FDA for ER+/HER2- Breast Cancer

Fineline Cube Aug 12, 2025

Arvinas, Inc. (NASDAQ: ARVN) and its partner Pfizer (NYSE: PFE) announced on August 8, 2025,...

Company Medical Device

J&J MedTech Gains China Approval for MENTOR MemoryGel Xtra Breast Implants

Fineline Cube Aug 12, 2025

US major Johnson & Johnson MedTech announced that its MENTOR MemoryGel Xtra Breast Implants have...

Posts pagination

1 … 109 110 111 … 659

Recent updates

  • Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate
  • Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
  • Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
  • Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
  • Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Company

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.